Posted on 12/10/2010 1:07:06 PM PST by NYer
SAN DIEGO, CA--(Marketwire - December 10, 2010) - Medistem Inc. (PINKSHEETS: MEDS) announced today peer-reviewed publication of its data on what is believed to be the first "combination therapy" adult stem cell protocol for spinal cord injury.
The patient treated, who was 29 years old at the time, suffered a spinal cord injury resulting from an airplane crash on May 13th of 2008. He had no walking ability, intermittent pain and loss of sexual function. The patient was injected with a combination universal donor stem cell therapy in November of 2008, and January and July of 2009. A gradual improvement was observed subsequent to each administration of stem cells.
Currently the patient has recovered sexual function, is walking, and has a dramatic reduction in pain symptoms.
The medical article describing the procedure was published in the peer-reviewed journal International Archives of Internal Medicine and was co-authored by scientists at the University of California San Diego, Indiana University, and University of Utah. It can be accessed at this link: http://www.intarchmed.com/content/pdf/1755-7682-3-30.pdf.
"While we cannot make any conclusions based on the treatment of only one patient, we are very excited to see such a drastic improvement," said Dr. Bogin, Chairman and President of Medistem.
Medistem is an adult stem cell company based in San Diego, California. The company has filed an Investigational New Drug Application (IND) with the FDA for use of its universal donor endometrial regenerative cells (ERC) for treatment of critical limb ischemia, an advanced form of peripheral artery disease. The Endometrial Regenerative Cells may be purchased for research use at the General Biotechnology LLC website: http://www.gnrlbiotech.com/?page=catalog_endometrial_regenerative_cells.
"We aim to initiate clinical trials in the US in the first quarter of 2011. Through this we hope to take data from promising case reports, such as the one discussed today, into the scientific framework required by the FDA for going down the path to full registration," said Dr. Sablin, Vice President of Medistem, who is also founder of Selena Pharmaceuticals and co-founder of the NASDAQ company Medivation Inc. "The fact that Endometrial Regenerative Cells can be made into lung, liver, brain, pancreatic, bone, fat, blood vessel, heart, and muscle tissue suggests that these cells may be useful for numerous diseases."
"To date we have published patient results in multiple sclerosis, heart failure, Duchenne Muscular Dystrophy, and now spinal cord injury," said Mr. Zaharchook, Vice Chairman and Board Member of the Company. "While we as a company are focused on our critical limb ischemia program, we are optimistic about the other clinically-applicable uses of the ERC and are currently seeking strategic partners."
About Medistem Inc.
Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company's lead product, the endometrial regenerative cell (ERC), is a "universal donor" stem cell being developed for critical limb ischemia. A publication describing the support for use of ERC for this condition may be found at http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf. ERC can be purchased for scientific use through Medistem's collaborator, General Biotechnology http://www.gnrlbiotech.com/?page=catalog_endometrial_regenerative_cells.
Catholic Ping
Please freepmail me if you want on/off this list
Re: #3 ... I expect the leftist secular media to ignore this development. It doesn’t support their baby-killing agenda.
But this is of no “value”,
because it doesn’t dehumanize the embryo.
And how are the “had-aborts” going to salve their consciences if the embryo isn’t dehumanized?
Can’t really be sure if natural healing took place or was caused by the introduction of “outside” stem cells.
I certainly would like to walk again.
Which raises an interesting question: How recent does the injury have to be, to be treated effectively?
And pro-lifers have traditionally very gullible targets for scammers.
Godspeed.
It may be substantive, but it's certainly stock hype. And pro-lifers have traditionally been very gullible targets for scammers.
Looks like you graduated from the DoughtyOne school of proofreading. ;-)
The Archives of Internal Medicine does not usually engage in stock hype. It’s a peer-reviewed scholarly journal and getting published in it is not easy.
This can’t be true! We all know (at least the media and the proponents have been telling us for years) that the only viable stem cells come from embryos!
/s
You can loosen your jaw, Jeeves. The financial press -- especially the online financial press -- will publish a story about your grandma being abducted by aliens if you pay them enough.
Gawdalmighty, do I have to publish freaking illustrated instructions on how to read a post?
sex cells. err, sells.
Non-matched stem cells?
Can they not harvest ‘adult’ stem cells from the adult being treated?
I read the post. And I understand about stock hype. But then I went to Pubmed to read more about the research, and it looks as though these people are headed in the right direction. Medical research is my area of specialty, so I do know how to read scholarly journal articles.
Hmmm. . .I don’t recall seeing that they’ve been able to do this with embryonic stem cells. (Or anything else for that matter.)
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.